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Abstract
Gray’s theory of personality postulates that fear and anxiety are distinct emotional systems with
only the latter being sensitive to anxiolytic drugs. His work was mainly based on animal
research, and translational studies validating his theory are scarce. Previous work in humans
showed an influence of the benzodiazepine lorazepam on both systems, however, dependent on
dosage (1 and 2 mg) and personality differences in negative emotionality. The present study
aims to replicate these findings, and in addition tests the drug threshold effect by introducing
a lower dosage of 0.5 mg lorazepam. Fifty healthy adults (23 males, agemean 22.40, SD ± 3.68)
participated in an experimental threat-avoidance paradigm designed to dissociate risk assess-
ment intensity (RAI, reflecting anxiety) and flight intensity (FI, reflecting fear) and completed
two self-report questionnaires assessing facets of negative emotionality (Spielberger State Trait
Anxiety Inventory and Fear Survey Schedule). In a randomized placebo-controlled within-
subjects design, 0.5 and 1 mg of lorazepam were applied per os. Saccadic peak velocity was
assessed by means of eye-tracking in order to control for sedating drug effects. Results showed
the expected and specific anxiolytic effect of lorazepam on RAI, however, only in the 0.5 mg
condition. FI was not influenced by lorazepam, and previous findings of interaction effects
of lorazepam with self-reported negative emotionality could not be corroborated. Overall, this
study demonstrates anxiolytic effects of lorazepam in dosages ≤1 mg in the absence of a drug
effect on fear using a translational behavioural task. However, a putative moderating role of
personality on defensive behaviour has to be clarified in future research.
1. Theoretical Background
The revised reinforcement sensitivity theory (r-RST) postulates that fear and anxiety are two
distinct neural affective systems (Gray & McNaughton, 2000). This hypothesis was based on
extensive animal research using pharmacological approaches. Anxiety is thought to be related
to defensive approach behaviour (comprising passive avoidance behaviour), whereas fear is
hypothesized to be related to defensive active avoidance behaviour. Stimuli that are new or
ambiguous, that is, where the potential consequences are unclear, stimulate the behavioural
inhibition system (BIS; the r-RST’s proxy for anxiety) and lead to increased attention, risk
assessment and checking of memory traces to investigate the potential threat of the stimuli.
The BIS is also activated by all kinds of goal conflicts, including approach–avoidance,
avoidance–avoidance and approach–approach conflicts. These conflicts represent uncertainty
and are accompanied by feelings of anxiety. In contrast, the fear system is triggered by clear
negative stimuli that need not be approached, but simply have to be avoided, or escaped from.
Defensive avoidance comprises three potential defensive behavioural consequences: fight, flight
and freeze (FFF-system; the r-RST’s proxy for fear). The perceived distance from the threat cru-
cially influences the choice of the respective behavioural alternatives. Freezing behaviour is acti-
vated if the perceived threat is close and impossible to escape. At a greater perceived distance of
the threat and if there is a possibility to escape, flight behaviour is elicited. However, when the
threat is so close that flight is not possible and freezing is not an appropriate reaction, defensive
threat occurs (such as vocalization and display of teeth or claws), followed by explosive defensive
attack at zero distance to threat (i.e. when nose-to-nose), that is, fight behaviour.
The hypothesis that fear and anxiety are distinct emotional systems is supported by exper-
imental pharmacological work, demonstrating that only anxiety but not fear can be influenced
by anxiolytic drugs (Gray & McNaughton, 2000).
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Gray’s r-RST was strongly influenced by seminal work by
Blanchard and Blanchard (1989), which showed that anxiety and fear
behaviour could be successfully differentiated in rodents. Blanchard
et al. (1990a) investigated anxiolytic drug effects with respect to risk
assessment behaviour in rodents. Rodents were exposed to different
types of threats reaching from mild threat (e.g. the odour of a preda-
tor) to severe threat (e.g. clear sights of a nearby predator) represent-
ing anxiety and fear, respectively. The results showed that the rodents’
state level of defensiveness determined the direction of anxiolytic
drug effects: The risk assessment of mildly threatened rodents was
reduced (Blanchard, Blanchard, Weiss & Meyer, 1990a), while the
risk assessment of severely threatened rodents was increased by anx-
iolytics (Blanchard, Blanchard, Tom & Rodgers, 1990b).
Despite convincing rodent studies, approaches attempting to
extrapolate these findings to humans are scarcer (e.g. Reuter,
Schmitz, Corr & Hennig, 2006). One of the most severe problems
of such translational work is to transform the phenotypes under
investigation from rodents to humans and vice versa. However,
recent neuroimaging studies have begun to test the neural net-
works Gray postulates for his distinct affective systems (Mobbs
et al., 2010; Montag, Basten, Stelzel, Fiebach & Reuter, 2010;
Patrick et al., 2019; Reuter et al., 2004) and there are also
approaches that tested the sensitivity to pharmacological chal-
lenges. For example, Grillon et al. (2006) investigated the effects
of the benzodiazepine alprazolam on cued fear and contextual
anxiety in a startle reflex paradigm containing three different con-
ditions. The conditions included predictable electric shock (i.e.
fear), unpredictable electric shock (i.e. anxiety) and no electric
shock. Results confirmed the assumption that cued fear is not sen-
sitive to alprazolam, whereas contextual anxiety is influenced by
alprazolam.Moberg and Curtin (2009) examined the effect of alco-
hol on startle responses in experimental conditions with predict-
able and unpredictable administration of electric shock. The
authors demonstrated that alcohol reduced the startle response
in unpredictable conditions but not in predictable conditions.
To further extent these translational findings in humans, we
adopted and translated a rodent model of fear and anxiety, the
Mouse Defense Test Battery (Blanchard, Griebel & Blanchard,
2003) into the Joystick Operated Runway Task (JORT; Perkins
et al., 2009). The JORT paradigm attempts to operationalize the
measurement of dissociable components of fear (flight intensity,
FI) and anxiety (risk assessment intensity, RAI) in humans [for
a detailed description (Methods section) and a critical review
(Discussion section) of this task see below].
In a first placebo-controlled pharmacological study on the
JORT, the effects of citalopram (10 mg) and lorazepam (1 mg) were
investigated in 30 healthy males. We hypothesized that lorazepam,
a benzodiazepine drug with well-established anxiolytic properties,
would alter behaviour reflecting anxiety but not fear. Conversely,
we hypothesized that citalopram, a selective serotonin reuptake
inhibitor with well-established anti-panic properties, would alter
fear behaviour but not anxiety behaviour. To test the interaction
between severity of stress and lorazepam, we considered individual
differences in human trait perception of threat intensity. To this we
administered the Fear Survey Schedule (FSS; Wolpe & Lang, 1974),
which consists of two major subscales: First, social fear measures a
mixture between trait anxiety and fear (Cooper, Perkins & Corr,
2007); and second, tissue-damage fear which constitutes a relatively
pure measure of fear (Perkins, Kemp & Corr, 2007). Furthermore,
we included the Y2 (trait) scale from the Spielberger State-Trait
Anxiety Inventory (STAI, Spielberger, Gorsuch, Lushene, Vagg &
Jacobs, 1983) in order to have a general measure of anxiety. We
found support that lorazepam modulated RAI. In addition, a par-
ticular strong anxiety reducing effect was observable in participants
scoring in the lower half of the sample on FSS social fear. These find-
ings were in line with prior delineated assumptions and provided
further evidence that human (trait) personality differences are com-
parable to experimentally induced (state) anxiety differences in
rodents. Contrary to our prior assumption, citalopram showed an
effect neither on RAI nor on FI. For this reason, we did not test cit-
alopram in follow-up studies.
In 2013, we built on our previous findings and tested the effects
of two different doses of lorazepam (1 and 2mg) versus placebo
(Perkins et al., 2013) in 40 healthy adults (20 females). Here, we
assumed that questionnaire scores of STAI-T would correlate
positively with RAI, whereas questionnaire scores of FSS would
correlate positively with FI. We additionally administered the
Eysenck Personality Questionnaire – Revised (Eysenck & Eysenck,
1991) to include neuroticism as a superordinate measure of prone-
ness to negative emotionality. We built our hypotheses on the
assumption of 2009. Therefore, lorazepam should increase RAI
in participants scoring high on trait anxiety but decrease RAI in
participants scoring low on trait anxiety. Furthermore, in line with
Gray’s theory, we did not expect an anxiolytic effect of lorazepam
on FI. As hypothesized, RAI was affected by lorazepam but the
effect was modulated by personality. A dose of 2 mg lorazepam
reduced RAI in low scorers on trait anxiety but increased RAI
in high scorers, whereas personality had no differential effects in
the placebo and 1mg lorazepam conditions. Against our predic-
tions, there was an interaction effect between lorazepam condition
and tissue-damage fear. Lorazepam increased FI in the participants
with low scores on FSS tissue damage in a dose-dependent manner,
whereas FI was decreased in participants with high FSS tissue dam-
age scores in a dose-dependent manner.
In sum, two consecutive pharmacological studies showed an
effect of lorazepam on defensive behaviour as measured by the
JORT, but the patterning of those effects varied between the two
studies. In the first study, 1 mg of lorazepam reduced behavioural
anxiety (RAI) but only in participants scoring low on the FSS social
fear, a hybrid measure of anxiety and fear. Conversely, in the sec-
ond study, only the dosage of 2 mg of lorazepam reduced RAI, but
this time only in participants scoring low in STAI-T. Furthermore,
in Study 2, against our theoretical predictions, a behavioural mea-
sure of fear (FI) was influenced dependent on dosage of lorazepam
and scores of the FSS tissue-damage fear scale. FI showed a
dose-dependent increase in participants scoring low and a dose-
dependent decrease in high-scoring participants.
Therefore, although both studies showed some overlap with
respect to their results, there are also some discrepancies especially
regarding which dosage of lorazepam showed significant effects on
defensive behaviour.
The present study was designed to further elucidate the effects of
lorazepamon defensive behaviour and its interactionwith personality
in an independent study with an increased sample size. We aimed to
balance gender and introduced a lower dosage of 0.5mg lorazepam in
order to obtain information on lorazepam’s low range threshold
effects by comparing it to the 1mg and the placebo condition.
2. Materials and Methods
2.1 Recruitment, inclusion and exclusion criteria
Participants were recruited through social media (e.g. Facebook),
student newsletters of the University of Bonn and flyers. For
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inclusion, participants had to be between 18 years and 35 years old,
healthy and right-handed. Exclusion criteria were consumption of
anymedication (except of oral contraceptives in women), a current
or past diagnosis of physical, neurological or psychiatric condition,
blood pressure below 100/60 or above 130/90, a bodymass index of
less than 18 or more than 30, injuries or diseases of the inner ear
accompanied by loss of hearing, colour-blindness, current or
recent (within the last 12 months) consumption of drugs or nico-
tine, earlier consumption of lorazepam or other benzodiazepines
during lifetime and for women a positive pregnancy test. The study
was approved by the research ethics committee of the Faculty of
Medicine at the University of Bonn.
The final sample consisted of 50 healthy participants (23 males;
mean age 22.40 years, SD ± 3.68). All were students of the
University of Bonn or neighbouring universities.
2.2 Screening
First, participants completed an online questionnaire intended to
verify whether they met the inclusion criteria and none of the
exclusion criteria. If so, participants were invited to a screening
in person to further ensure that they fulfil all conditions of partici-
pation. They first gave written, informed consent and declared
their willingness in principle to participate in the experiments.
Then, they were screened with in-depth interviews for the exist-
ence of any psychiatric, neurological or physical disorders.
Height, weight and blood pressure were measured. The absence
of colour-blindness was verified by two red–green pictures of
the Ishihara colour test. Additionally, the absence of drug con-
sumption and, in females, the absence of pregnancy were tested.
Finally, all participants completed the Edinburgh Handedness
Inventory (Oldfield, 1971), the FSS and the STAI-T.
2.3 Study protocol
We used a double-blind, placebo-controlled, randomized, within-
subjects design. Each participant received placebo, 0.5 and 1 mg
lorazepam, with order of administration following a Latin square
design. Assessments were scheduled a week apart to allow drug
washout.
After arriving in the laboratory, participants were once again
briefly checked for health. Female participants underwent urine
pregnancy tests before all three experimental sessions to confirm
the absence of pregnancy. During the assessments, participants
were allowed to drink as much still water as they liked but were
not allowed to eat or drink anything else. Tablets were adminis-
tered with still water and, due to our double-blind study design,
were contained in opaque capsules. Due to the pharmacokinetics
of lorazepam, there was a 2 h wait from capsule administration
until the actual experimental session started (Kyriakopoulos,
Greenblatt & Shader, 1978).
All assessments started with JORT, followed by the saccade task.
JORT took approximately 20 min and saccades a further 2 min.
Subsequently, participants carried out four further tasks not
reported in this paper (saccadic adaptation task, antisaccade task,
Simon task, flanker task). An overview on the study protocol can be
seen in Figure 1.
2.4 Joystick Operated Runway Task
Human defensive behaviour was measured by the JORT (Perkins
et al., 2009, 2013). The paradigm allows the measurement of
the putatively dissociable components of fear (FI, referred to as
one-way avoidance) and anxiety (RAI, referred to as two-way
avoidance). Behavioural data were acquired using a force-sensing
joystick apparatus (PH-JS1, Psyal, London, UK). The harder the
joystick was pushed, the faster the cursor (green dot) moved.
As can be seen in Figure 2, a vertically orientated image of a
runway was projected on the computer monitor. The green dot
was representing the participant and movable by pushing the joy-
stick. Contrary to our first study but in accordance to our second
study from 2013, we did not calibrate the participants’ minimum
force required for the green dot to reach escape velocity. Therefore,
all participants had to spend the same strength to move the green
dot, regardless of differences in absolute physical strength.
In addition to the green dot, one or two computer controlled red
dots appeared on the screen. To control for individual differences
in participants’ motor function and sedation effects of lorazepam,
responses were measured with and without threat, as signalled by
the presence or absence, respectively, of a lightning flash icon on
screen. In the event of a collision, when the lightning flash icon was
present, participants received an unpleasant but harmless 115-dB
white noise burst of near instantaneous rise time lasting 250 ms
through headphones.
In the one-way avoidance (Figure 2(a) and (b), representing FI),
the cursor (green dot) was pursued by a single threat stimulus (red
dot). The degree to which threat (presence of the lightning flash
icon, Figure 2(b)) increased the velocity of the green dot along
the runway is related to FI. Backward movements were not pos-
sible. FI scores were calculated as the average velocity in trials that
contained no threat of white noise (Figure 2(a)) subtracted from
the average velocity in trials with a threat of white noise
(Figure 2(b)).
The two-way active avoidance tasks (Figure 2(c) and (d), rep-
resenting RAI) were identical, except that a second red dot trav-
elled ahead of the green dot at a constant velocity, causing a
goal conflict whereby the participant had to travel fast enough
to avoid the pursuing threat, but not so fast that they collided with
the leading threat stimulus. The degree to which threats (as sig-
nalled by the lightning flash icon) increased the magnitude of
forward–backward oscillation of the participants when trapped
between the two red dots represents RAI-related goal conflicts.
Similar to the calculation of FI scores, RAI scores were calculated
as the standard deviation (SD) of the average velocity in trials that
contained no threat of white noise (Figure 2(c)) subtracted from
SD of the average velocity in trials with a threat of white noise
(Figure 2(d)).
Each testing session consisted of 12 trials of each of the above
described types. In total, 48 trials were presented in a pseudo-
random order as well as the intertrial intervals were varied
pseudo-randomly (between 15 and 30 s). Both experimental
manipulations served to enhance unpredictability. Trials termi-
nated automatically by collision between the green and the red
dot. Therefore, in threatening trials, participants were only briefly
exposed to white noise. Each trial had a maximum duration of 7 s.
Trials without collision terminated automatically after this dura-
tion. An early collision did not alter the overall duration of the trial.
2.5 Saccade task
Saccades were recorded using an EyeLink 1000 video-based eye-
tracker (SR Research Ltd., Ontario, Canada), which records at a
sampling frequency of 1,000 Hz. Participants were seated 70 cm
away from the centre of the computer screen (1600 × 1050 pixels,
60 Hz refresh rate) with their head resting on a chin rest to stabilize
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head position. A five-point horizontal/vertical calibration was con-
ducted prior to the task.
At the beginning of each trial, a central fixation point, a white
circle approximately 0.35° of visual angle in diameter, was pre-
sented on a black background in the middle of the computer
screen. The central fixation point was presented for 500–
1,500 ms and was followed by a peripheral target of identical
dimensions and appearance presented in one of four locations
(±7.25°; ±14.5° horizontally from the fixation point).
Participants completed 60 trials in total, with each location pre-
sented 15 times, in random order. Participants were instructed
to look at the fixation point as soon as it appeared on the screen
and to redirect their gaze to the peripheral target when it appeared
as fast and accurately as possible.
Saccades were identified using the Data Viewer software pack-
age (SR Research) and defined as eye movements having a mini-
mum amplitude of 1°, a minimum velocity of 30°/s and a
minimum latency to peripheral stimulus of 70 ms. The dependent
variable was the peak velocity (in °/s) of the first valid saccade to
the peripheral stimulus. Building on findings that sedation reli-
ably leads to reduced saccadic peak velocity (de Visser et al.,
2003; Ettinger et al., 2018; Reilly, Lencer, Bishop, Keedy &
Figure 1. Study protocol. Further tasks: saccadic adapta-
tion task, antisaccade task, Simon task, flanker task.
4 JV Lippold et al.
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Sweeney, 2008), this measure was used as an objective behaviou-
ral marker of the sedative effects of lorazepam in the absence of
exposure to threat.
2.6 Questionnaires
In order to replicate our earlier findings (Perkins et al., 2009, 2013),
we chose the same questionnaires as in those studies. First, the FSS
(Wolpe & Lang, 1974) was administered. The FSS consists of two
major subscales. Social fear measures a mixture of trait anxiety and
fear (Cooper et al., 2007). Tissue-damage fear constitutes a rela-
tively pure measure of fear (Perkins et al., 2007). Second, we
administered the STAI (Spielberger et al., 1983) as a specific mea-
surement of anxiety. Contrary to our study in 2013, we did not
administer the Eysenck Personality Questionnaire – Revised
(Eysenck & Eysenck, 1991), as we found during that study that
the EPQ neuroticism dimension correlates so strongly with trait
anxiety (r = .825) that it is effectively redundant.
2.7 Statistics
Statistical analyses were performed using the Statistical Package for
the Social Sciences (SPSS version 25). Reliabilities of personality
measures were calculated in terms of internal consistencies
(Cronbach’s α). Associations between dependent variables in the
JORT and scores on FSS and STAI-T were assessed using
Pearson’s product–moment correlations. For the analysis of effects
of drug on the intensity of threat-avoidance behaviour, partici-
pants with scores of three SDs above or below mean scores of
the sample were considered to be outliers and excluded. For this
reason, 2 participants were excluded for the analysis of FI (final
sample N = 48, 26 females) and 10 participants were excluded
for the analysis of RAI (final sample N = 40, 21 females).
Learning effects were calculated by repeated measures analysis
of variance (ANOVA), with the three testing sessions as a three-
level-within-subjects factor. To investigate the effects of loraze-
pam, further ANOVAs, with dosage (placebo, 0.5 and 1 mg
lorazepam) as a three-level-within-subjects factor were calculated.
In a further step, scores of the three personality questionnaires
scales were divided at the sample’s median. Then, these dichoto-
mous variables were entered as a between-subject factor into sep-
arate repeated measures ANOVAs. To control for gender effects,
gender was entered as an additional between-subject factor into
the repeated measures ANOVAs.
Finally, to control for sedative effects of lorazepam, we calcu-
lated a further repeated measures ANOVA with the three different
drug conditions as within-subjects factor and prosaccade peak
velocity as dependent variable. Five participants with less than 3
valid trials in one or more of the four locations were excluded from
peak velocity analyses. Also, the prosaccade peak and the JORT
variables FI and RAI were correlated in order to test if possible drug
effects on fear and anxiety were related to general sedative effects of
lorazepam. For all ANOVAs with significant results, post-hoc
t-tests for dependent samples were calculated to identify which
particular differences between pairs of means are significant.
Moreover, post-hoc power analyses were calculated to assess the
statistical power of all ANOVAs and significant results were
Bonferroni corrected for multiple testing.
3. Results
3.1 Reliabilities of personality measures
The reliabilities in terms of internal consistencies (Cronbach’s α)
were as follows: STAI-T: n = 20, α = .91, tissue-damage fear:
n = 32, α = .90; social fear: n = 32, α = .93.
3.2 Personality effects on task performance
Descriptive statistics and intercorrelations of self-report and per-
formancemeasures are depicted in Table 1. In terms of correlations
with defensive behaviour, bivariate correlations only showed a sig-
nificant correlation between FSS tissue-damage fear and RAI in the
placebo condition. There were no further significant correlations
Figure 2. (a and b). One-way avoidance, labelled flight
intensity (FI); (a) (on the left, without a lightning flash icon)
A collision of the red and green dot led to no consequences;
(b) (on the right, with a lightning flash icon) If the red dot
collided with the green dot, participants received an
unpleasant white burst. (c and d): Two-way avoidance,
labelled risk assessment behaviour (RAI); (c) (on the left,
without a lightning flash icon) A collision of one of the red
dots and the green dot led to no consequences; (d) (on
the right, with a lightning flash icon) If one of the two red dots
collided with the green dot, participants received an
unpleasant white burst.
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between self-reported questionnaires scores with dependent
behavioural variables in the JORT.
3.3 Learning effects on RAI and FI
Evaluating the behavioural JORT data according to the time-point
of testing, there was a learning effect neither on RAI (F(2,78) =
0.900, p = .411, power: .200) nor on FI (F(1.576,74.053) = 0.062,
p = .902, power: .058).
3.4 Effects of lorazepam on RAI and FI
Results show a significant main effect of dosage on RAI (F(2, 78) =
5.178, p = .008, η2 = .117, power = .814; see Figure 3). After
Bonferroni correction formultiple testing, this effect is still significant.
It also remained significant when outliers were included (F(2,98) =
3.718, p = .028, η² = .071, power: .669).
Post-hoc tests showed significant lower RAI scores in the
0.5 mg condition than in the placebo and the 1 mg condition.
There was no significant difference between the placebo and the
1 mg condition. Also, there was no main effect of dosage on FI
(F(2,94) = 0.346, p = .708, power: .104).
3.5 Interaction effects of lorazepam and personality on RAI
There was neither a main effect of STAI-T (F(1,38) = 0.817, p = .372,
power: .143) nor an interaction effect of STAI-T by dosage on RAI
(F(1.727,65.634) = 0.811, p= .433, power: .184). Regarding the FSS, sim-
ilar results were observed: There was a main effect neither of FSS
social fear on RAI (F(1,38) = 3.154, p = .084, power: .410) nor of
FSS tissue damage on RAI (F(1,38) = 1.903, p = .176, power: .270).
Also, there was neither an interaction effect of FSS social fear by dos-
age on RAI (F(2,76) = 0.087, p= .917, power: .063) nor an interaction
effect of FSS tissue damage by dosage on RAI (F(2,76) = 1.102, p =
.337, power: .237).
3.6 Interaction effects of lorazepam and personality on FI
Results regarding interaction effects of lorazepam and personality
on FI are similar to the RAI results. There was neither a main effect
of STAI-T (F(1,46)= 0.033, p= .856, power: .054) nor an interaction
effect of STAI-T by dosage on FI (F(1.769,81.371) = 1.305, p = .275,
power: .260). Also, interactions with the FSS questionnaire showed
no significant results: There was neither a main effect of FSS social
fear (F(1,46)= 0.529, p= .471, power: .110) nor an interaction effect
of FSS social fear by dosage on FI (F(2,92) = 1.037, p = .359, power:
.148), and there was neither a main effect of FSS tissue damage
(F(1,46) = 0.858, p = .359) nor an interaction effect of FSS tissue
damage by dosage on FI (F(2,92) = 1.441, p = .242, power: .301).
3.7 Gender effects
There was neither a main effect nor two-way interactions (gender
by dosage, gender by personality) or a three-way interaction
(gender by dosage by personality) effect of gender on RAI or FI.
All interactions with personality were tested separately for the
three variables FSS social fear, FSS tissue damage and STAI-T.
3.8 Drug effects on saccadic peak velocity
Repeated measures analysis of variance showed a significant main
effect of drug condition on prosaccade peak velocity (F(2,88) =
12.274, p < .001, η2 = .218, power: .995). Additional analyses
showed that the 0.5 mg lorazepam condition significantly
decreased peak velocity as compared to placebo (T(44) = 2.878,
p = .006; see descriptive statistics of the saccadic peak velocity in
Table 2). Onemg lorazepam significantly decreased the peak veloc-
ity compared to the placebo condition (T(44) = 4.855, p < .001) as
well as compared to the 0.5 mg lorazepam condition (T(44) = 2.110,
p = .041). Table 2 shows correlations between prosaccade peak
velocity and the JORT variables of FI and RAI. No significant cor-
relations between the lorazepam effects were observable, indicating
Table 1. Means, standard deviations and intercorrelations of self-reported and behavioural measures of defensive behaviour
Variable Mean (SD) 1 2 3 4 5 6 7 8
1. Trait anxiety 33.8 (7.99) –
2. Tissue-damage fear 18.16 (11.77) 0.343* –
3. Social fear 24.34 (14.43) 0.575** 0.761** –
4. FI (placebo) 0.51 (0.79) −0.185 −0.161 −0.246 –
5. FI (0.5 mg lorazepam) 0.59 (0.76) −0.077 −0.006 −0.020 0.277 –
6. FI (1 mg lorazepam) 0.51 (0.64) 0.037 −0.249 −0.084 0.259 0.472** –
7. RAI (placebo) 0.11 (0.14) 0.020 0.331* 0.179 0.394* 0.364* 0.164 –
8. RAI (0.5 mg lorazepam) 0.00 (0.25) −0.118 −0.197 0.104 0.027 −0.064 −0.008 −0.151 –
9. RAI (1 mg lorazepam) 0.09 (0.17) −0.126 0.091 0.159 0.056 0.178 0.495** 0.184 0.055
Correlations reflect Pearson’s product–moment correlation coefficients. *p< .05; **p< .01.
Figure 3. Main effect of dosage on RAI, means and standard error of means (SEM).
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that sedative effects of lorazepam were not responsible for altering
the defensive behaviour of participants.
4. Discussion
Building on the results of two previous studies of our group, which
demonstrated effects of lorazepam on defensive behaviour, the aim
of the present study was to partially replicate the findings and to
extend our knowledge on lower dosage threshold and moderating
effects of personality. Given that the results of the studies by
Perkins et al. (2009, 2013) showed some inconsistencies, the need
for a replication study was apparent. The discrepancies between
the studies were particularly evident with regard to the dosage
of lorazepam showing effects on defensive behaviour. As putative
causes, we assumed differences in sample size and gender distribu-
tion across studies. Therefore, we increased the sample size and
aimed for an approximately equal gender distribution. Also, we
introduced a lower dosage of lorazepam (0.5 mg) to obtain infor-
mation on lorazepam’s threshold effects. Apart from this, the
present study protocol was very similar to the one used in
Perkins et al. (2013).
Although the present study showed an effect of lorazepam on
defensive behaviour independent of sedative effects of the drug as
assessed by changes in peak velocities in the prosaccades, the dis-
crepancies between the two earlier studies could not be conclu-
sively clarified. In terms of main effects, in the Perkins et al.
(2009) study there was a significant main effect of drug on RAI
but not on FI. In the Perkins et al. (2013) study, there was no main
effect of drug on RAI but on FI. In terms of personality modulation
in Perkins et al. (2009), RAI was reduced by 1 mg of lorazepam in
participants scoring low on FSS social fear. This was not observable
in participants with high FSS social fear scores. The results in
Perkins et al. (2013) presented a different picture. A 2 mg dose
of lorazepam reduced RAI but only in participants scoring low
in STAI-T. In the FI condition, lorazepam caused a dose-depen-
dent increase on FI in participants scoring low on FSS tissue-dam-
age fear and a dose-dependent decrease on FI in high-scoring
participants on FSS tissue-damage fear. In the present study, none
of these results were replicated except the main effect of lorazepam
on RAI, but this was driven by the 0.5 mg dose of lorazepam – the
1 mg dose did not separate significantly from placebo.
To explain the unexpected effect of no difference between the
1 mg dose and placebo, we critically analysed the computation of
our RAI score in the JORT paradigm. As described in the method
section, the dependent variable is calculated as the SD of the aver-
age velocity in trials that contained no threat of white noise
(Figure 2(c)) subtracted from the SD of the average velocity in trials
with a threat of white noise (Figure 2(d)). Thus, the RAI score rep-
resents a difference between two variables and, consequently, the
dependent variable can be influenced by two different parameters.
First, RAI scores decrease when the SD of the average velocity in
trials with a threat of white noise decreases and the SD of the aver-
age velocity in trials with no threat is unchanged. This is what we
expect as an actual anxiolytic effect of lorazepam. Second, it could
also be that a reduced RAI score is due to a higher velocity in trials
that contained no threat of white noise than in trials with a threat.
In order to test both possibilities, we looked at the velocities in the
threat and the no threat conditions separately for each dosage (pla-
cebo, 0.5 and 1 mg). The pattern of results for this additional analy-
sis can be seen in Figure 4.
It can be seen that the effect of 0.5 mg lorazepam is driven by
both factors: as expected, the SD of the average velocity in trials that
contained a threat of white noise decreased, but additionally, the
SD in trials that contained no threat of white noise increased,
thereby strengthening the decrease of the RAI score representing
the difference between both conditions. Of particular interest is the
pattern of results in the 1 mg condition as compared to the placebo
condition because the RAI scores (difference scores) in these two
conditions do not differ but the absolute values in the threat and
the no threat condition differ strongly (higher values in the placebo
condition than in the 1 mg condition). Overall, on the descriptive
level, there is an anxiolytic effect of lorazepam irrespective of dos-
age if only the raw data in the threat condition are considered
(higher scores in the placebo condition than in both lorazepam
conditions). Therefore, the significant effect in the 0.5 mg condi-
tion is caused not only by the anxiolytic effect in the threat condi-
tion but also by the relatively high scores in the no threat condition.
In sum, the additional analysis suggests that the trials without
threat are also aversive and therefore are able to evoke risk assess-
ment and accordingly are sensitive to the influence of lorazepam.
From these results, we derive that a low dosage of 0.5 mg is particu-
larly effective in high threatening situations but less in low threat-
ening situations. But by increasing the dosage, also lower
threatening situations are influenced by the anxiolytic effects of
Figure 4. Results of supplementary post-hoc analyses with respect to RAI raw scores.
Table 2. Means, standard deviations and correlations of defensive behaviour
and eye movements.
Variable Mean (SD) 1 2 3
1. Prosaccade Peak Velocity
placebo
337.59 (41.43) –
2. Prosaccade Peak Velocity
0.5 mg
324.89 (47.55) .787** –
3. Prosaccade Peak Velocity
1 mg
315.40 (48.15) .776* .801** –
4. Flight Intensity placebo .550 (.76) .112 .009 .047
5. Flight Intensity 0.5 mg .562 (.72) –.182 –.124 –.043
6. Flight Intensity 1 mg .509 (.63) –.044 –.076 –.208
7. Risk Assessment placebo .110 (.15) –.110 .019 .095
8. Risk Assessment 0.5 mg –.000 (.21) –.055 .038 .076
9. Risk Assessment 1 mg .088 (.16) .003 .079 –.150
Correlations reflect Pearson’s product–moment correlation coefficients *P<0.05; **P<0.01.
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lorazepam. The question of where the exact threshold between
high and low threatening situations remains open and needs fur-
ther research. The relatively high RAI scores in the no threat con-
dition can be explained by the nature of the JORT paradigm
(Perkins et al., 2019). The entire JORT situation is an anxiety-
inducing approach to threat and goal conflict in that participants
are volunteering to enter a testing room where they know (due to
the informed consent process) theywill receive a nasty burst of white
noise. So this idea does make it likely there will be some anxiety
experienced across the entire task, even in the non-threat RAI trials
a hypothesis that is supported by the additional findings depicted in
Figure 4. Perkins et al. (2019) described this phenomenon “the
experiment knowledge problem”, something which does not affect
rodents because they do not realize they are in an experiment.
Taking into account our new data, the overall view of the drug
effects in all three studies suggests that lorazepam does alter defen-
sive behaviour in humans but that the patterning of that effect is
highly variable and depends on certain conditions as described
above. It is unlikely that the patterns of results are due to gender
effects. In Perkins et al. (2009), only male participants were
included, but neither in Perkins et al. (2013) nor in the current
study, interactions between drug effects and gender were observed.
Furthermore, we cannot explain our divergent results by our larger
sample size, because due to the exclusion of 10 participants in the
two-way avoidance condition, the sample was nearly of the same
size compared to Perkins et al. (2013).
We found a significant main effect of drug condition on FI in
Perkins et al. (2013) study but not in Perkins et al. (2009) or the
present study. Furthermore, in Perkins et al. (2009) and in the cur-
rent study, there were no interaction effects between fear and anxi-
ety questionnaires and dosage of lorazepam on FI. This was
different in Perkins et al. (2013): There was a significant interaction
between dosage of lorazepam and scores on FSS tissue-damage fear.
In participants scoring high on FSS tissue damage, FI scores were
decreased, whereas in participants scoring low on FSS tissue damage
FI scores were increased. Post-hoc contrasts showed that this
interaction was due to the difference between the 2mg condition
and the placebo condition. Unfortunately, we are not able to test this
interaction in the Perkins et al. (2009) or in the current study, as
2 mg lorazepam was not administered in those studies.
Some limitations of the present study have to be noted. First,
there are shortcomings regarding the operationalization of defen-
sive behaviour inherent to the JORT paradigm. JORT is not able to
measure all components of defensive behaviour. On the one hand,
this concerns the measurement of anxiety. For example, anxiety-
related hyper-scanning or checking of memory traces could not
be operationalized. Approach withdrawal oscillation constitutes
an important facet of anxiety, but the other components of anxiety
are also of importance. On the other hand, Gray (Gray &
McNaughton, 2000) postulated three different components of fear
behaviour, namely fight, flight and freezing. In the JORT, only
flight behaviour is operationalized. Participants can only push
the joystick forward in order to escape; not pushing the joystick
(freezing) is not an alternative, as than the collision is inevitable.
Alternative behavioural options reflecting fight behaviour are
not included in the paradigm at all.
Another point concerns the knowledge available about the
experimental situation including particularly the information on
being threatened by a very unpleasant noise (see above). This is
in contrast to the animal studies where rodents were struck
by the threat unexpectedly (Blanchard & Blanchard, 1989).
Therefore, the definition of fear-related behaviour, as solely threat
avoidant, is not reflected in the JORT. The rationale is that the
entire testing session may be understood as an approach-to-threat
situation which should theoretically elicit anxiety. This assumption
complicates a clear differentiation of fear and anxiety within the
JORT paradigm and could be related to the heterogeneous findings
in our three studies. In particular, FI scores are more difficult to
interpret, also considering the influence of lorazepam and the
interactions with personality questionnaires. For ethical reasons,
it is difficult to modify the experimental conditions in a way that
the threat hits the participants by surprise without being informed
prior to testing. However, the operationalization of FI was consis-
tent across all three studies and, therefore, it can be excluded that
this is the explanation for the inconsistent findings.
Interindividual differences in the perception of task difficulty
can be a further limitation of the JORT paradigm. The require-
ments, which must be met to prevent a collision of the green
dot with any red dot, could be easier for some participants than
for others. It may also be possible that the requirements are too
easy for individual participants and therefore neither anxiety
nor fear is triggered in these participants. Also, the familiarity with
similar games that are either also played with a joystick or games
with a similar design (e.g. the arcade game Pac-Man) can matter.
So far, we did not include questions covering these possible
influences on performance in the JORT paradigm.
Finally, it can be argued that the JORT lacks ecological validity.
At least for some participants it may seem more like a game which
has little to do with the fears and threats of daily life, especially
complex, abstract social anxiety which is likely to be more salient
to humans than rodents. Creating an experimental situation with
more ego-involvement of the participants, that shows more resem-
blance to reality and that is also able to differentiate all three sub-
components of the FFFS, would be favourable.
5. Conclusions
Overall, and in line with Gray’s r-RST, the present study demon-
strates anxiolytic effects of lorazepam in dosages ≤1 mg in the
absence of a drug effect on fear using a translational behavioural
task. However, the moderating role of personality on defensive
behaviour has to be clarified in future research.
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Acknowledgment.The authors would like to thankDr BehremAslan for clini-
cal support and Dr Katharina Bey for technical support.
Conflict of Interest. The authors declare no conflicts of interest.
References
Blanchard, R. J., & Blanchard, D. C. (1989). Attack and defense in rodents as
ethoexperimental models for the study of emotion. Progress in Neuro-
Psychopharmacology and Biological Psychiatry, 13, S3–S14. https://doi.org/
10.1016/0278-5846(89)90105-X.
Blanchard, D. C., Blanchard, R. J., Tom, P., & Rodgers, R. J. (1990b).
Diazepam changes risk assessment in an anxiety/defense test battery.
Psychopharmacology, 101, 511–518. https://doi.org/10.1007/BF02244230.
Blanchard, R. J., Blanchard, D. C., Weiss, S. M., & Meyer, S. (1990a). The
effects of ethanol and diazepam on reactions to predatory odors.
Pharmacology Biochemistry and Behavior, 35, 775–780. https://doi.org/10.
1016/0091-3057(90)90357-N.
8 JV Lippold et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/pen.2020.1
Downloaded from https://www.cambridge.org/core. IP address: 138.40.68.73, on 09 Sep 2020 at 15:25:37, subject to the Cambridge Core terms of use, available at
Blanchard, D. C., Griebel, G., & Blanchard, R. J. (2003). The mouse defense
test battery: Pharmacological and behavioral assays for anxiety and panic.
European Journal of Pharmacology, 463, 97–116. https://doi.org/10.1016/
S0014-2999(03)01276-7.
Bond, A., & Lader, M. (1974). The use of analogue scales in rating subjective
feelings. British Journal of Medical Psychology, 47, 211–218. https://doi.org/
10.1111/j.2044-8341.1974.tb02285.x.
Cooper, A. J., Perkins, A. M., & Corr, P. J. (2007). A confirmatory factor ana-
lytic study of anxiety, fear, and behavioral inhibition system measures.
Journal of Individual Differences, 28, 179–187. https://doi.org/10.1027/
1614-0001.28.4.179.
de Visser, S. J., van der Post, J. P., de Waal, P. P., Cornet, F., Cohen, A. F., &
van Gerven J. M. (2003). Biomarkers for the effects of benzodiazepines in
healthy volunteers. British Journal of Clinical Pharmacology, 55, 39–50.
https://doi.org/10.1046/j.1365-2125.2002.t01-10-01714.x.
Ettinger,U.,Meyhöfer, I.,Mehta,M.A., Kumari,V.,Corr, P. J.,Williams, S. C.,&
Perkins, A.M. (2018). Effects of lorazepam on saccadic eyemovements: The role
of sex, task characteristics and baseline traits. Journal of Psychopharmacology, 32,
678–690. https://doi.org/10.1177/0269881118772450.
Eysenck, H. J., & Eysenck, S. B. G. (1991). Eysenck personality scales (EPS
Adult). London: Hodder & Stoughton.
Gray, J. A., & McNaughton, N. (2000). The neuropsychology of anxiety (2nd
edition). Oxford: Oxford University Press.
Grillon, C., Baas, J. M., Pine, D. S., Lissek, S., Lawley, M., Ellis, V., & Levine, J.
(2006). The benzodiazepine alprazolam dissociates contextual fear from cued
fear in humans as assessed by fear-potentiated startle. Biological Psychiatry, 60,
760–766. https://doi.org/10.1016/j.biopsych.2005.11.027.
Hart, S. G., & Staveland, L. E. (1988). Development of NASA-TLX (task load
index): Results of empirical and theoretical research.Advances in Psychology,
52, 139–183. https://doi.org/10.1016/S0166-4115(08)62386-9.
Hommel, B. (2011). The Simon effect as tool and heuristic. Acta Psychologica,
136, 189–202. https://doi.org/10.1016/j.actpsy.2010.04.011.
Ishihara, S. (1960). Tests for colour-blindness. Japan: Kanehara Shuppan
Company. https://doi.org/10.1111/j.1469-8986.2006.00403.x.
Kyriakopoulos, A. A., Greenblatt, D. J., & Shader, R. I. (1978). Clinical phar-
macokinetics of lorazepam: A review. The Journal of Clinical Psychiatry, 39,
16–23.
Lappin, J. S., & Eriksen, C. W. (1966). Use of a delayed signal to stop a visual
reaction-time response. Journal of Experimental Psychology, 72, 805–811.
https://doi.org/10.1037/h0021266.
Mobbs, D., Yu, R., Rowe, J. B., Eich, H., FeldmanHall, O., & Dalgleish, T.,
(2010). Neural activity associated with monitoring the oscillating threat
value of a tarantula. Proceedings of the National Academy of Sciences of the
United States of America, 107, 20582–20586. https://doi.org/10.1073/pnas.
1009076107.
Moberg, C. A., & Curtin, J. J. (2009). Alcohol selectively reduces anxiety but
not fear: Startle response during unpredictable versus predictable threat.
Journal of Abnormal Psychology, 118, 335–347. https://doi.org/10.1037/
a0015636.
Montag, C., Basten, U., Stelzel, C., Fiebach, C. J., & Reuter, M. (2010). The
BDNF Val66Met polymorphism and anxiety: Support for animal knock-in
studies from a genetic association study in humans. Psychiatry Research, 179,
86–90. https://doi.org/10.1016/j.psychres.2008.08.005.
Oldfield, R. C. (1971). The assessment and analysis of handedness: The
Edinburgh inventory. Neuropsychologia, 9, 97–113. https://doi.org/10.
1016/0028-3932(71)90067-4.
Patrick, F., Kempton, M. J., Marwood, L., Williams, S. C., Young, A. H., &
Perkins, A. (2019). Brain activation during human defensive behaviour: A
systematic review and preliminary meta-analysis. Neuroscience &
Biobehavioral Reviews, 98, 71–84. https://doi.org/10.1016/j.neubiorev.2018.
12.028.
Perkins, A. M., Ettinger, U., Davis, R., Foster, R., Williams, S. C., & Corr, P. J.
(2009). Effects of lorazepam and citalopram on human defensive reactions:
Ethopharmacological differentiation of fear and anxiety. Journal of
Neuroscience, 29, 12617–12624. https://doi.org/10.1523/JNEUROSCI.2696-
09.2009.
Perkins, A. M., Ettinger, U., Weaver, K., Schmechtig, A., Schrantee, A.,
Morrison, P. D., : : : Corr, P. J. (2013). Advancing the defensive explana-
tion for anxiety disorders: Lorazepam effects on human defense are system-
atically modulated by personality and threat-type. Translational Psychiatry,
3, e246. https://doi.org/10.1038/tp.2013.20.
Perkins, A. M., Kemp, S. E., & Corr, P. J. (2007). Fear and anxiety as separable
emotions: An investigation of the revised reinforcement sensitivity theory of
personality. Emotion, 7, 252–261. https://doi.org/10.1037/1528-3542.7.2.
252.
Perkins, A. M., Strawbridge, R., Arnone, D., Williams, S. C., Gasston, D.,
Cleare, A. J., : : : Corr, P. J. (2019). Towards a neuroscience-based theory
of personality: Within-subjects dissociation of human brain activity during
pursuit and goal conflict. Personality Neuroscience, 2, e4. https://doi.org/10.
1017/pen.2019.2.
Reilly, J. L., Lencer, R., Bishop, J. R., Keedy, S., & Sweeney, J. A. (2008).
Pharmacological treatment effects on eye movement control. Brain
Cognition, 68, 415–435. https://doi.org/10.1016/j.bandc.2008.08.026.
Reuter, M., Schmitz, A., Corr, P. J., & Hennig, J. (2006). Molecular genetics
support Gray’s personality theory: The interaction of COMT and
DRD2 polymorphisms predicts the behavioral approach system.
International Journal of Neuropsychopharmacology, 9, 155–166. https://
doi.org/10.1017/S146114570500541.
Reuter, M., Stark, R., Hennig, J., Walter, B., Kirsch, P., Schienle, A., &
Vaitl, D. (2004). Personality and emotion: Test of Gray’s personality
theory by means of an fMRI study. Behavioral Neuroscience, 118, 462–
469. https://doi.org/10.1037/0735-7044.118.3.462.
Spielberger, C. D., Gorsuch, R. L., Lushene, P. R., Vagg, P. R., & Jacobs, A. G.
(1983). Manual for the state-trait anxiety inventory (form Y). Palo Alto, CA:
ConsultingPsychologists. https://doi.org/10.1002/9780470479216.corpsy0943.
Wolpe, J., & Lang, P. J. (1974). A Fear Survey Schedule for use in behavior
therapy. In E. J. Thomas (Ed.), Behavior modification procedure: A source-
book (pp. 228–232). New Brunswick, NJ: Aldine Transaction.
Personality Neuroscience 9
https://www.cambridge.org/core/terms. https://doi.org/10.1017/pen.2020.1
Downloaded from https://www.cambridge.org/core. IP address: 138.40.68.73, on 09 Sep 2020 at 15:25:37, subject to the Cambridge Core terms of use, available at
